Sionna Therapeutics, Inc. (SION)
NASDAQ:SION
Want to see SION full AI Analyst Report?
SION Stock Chart & Stats
$43.54
$0.55(1.26%)
At close: 4:00 PM EST
$43.54
$0.55(1.26%)
Day’s Range― - ―
52-Week Range$13.51 - $48.45
Previous CloseN/A
Volume33.51K
Average Volume (3M)377.17K
Market Cap
$1.62B
Enterprise Value$1.88B
Total Cash (Recent Filing)$216.15M
Total Debt (Recent Filing)$8.38M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 17, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding45,150,330
10 Day Avg. Volume369,735
30 Day Avg. Volume377,169
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.36
Price to Sales (P/S)0.00
P/FCF Ratio-24.66
Enterprise Value/Market Cap1.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.15K
Enterprise Value/Ebitda-22.84
Forecast
1Y Price Target
$51.71Price Target Upside18.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted CFTR Small-molecule PipelineSionna’s business model is concentrated on small-molecule therapies that target underlying CFTR protein dysfunction in cystic fibrosis. This disease-modifying focus addresses an enduring unmet medical need and positions the company in a structurally attractive niche where successful candidates can secure long-term demand and durable clinical value.
Materially Strengthened Balance SheetA materially improved capital base with $306.8M of equity and very low leverage reduces near-term solvency and refinancing risk. For a pre-revenue biotech, this stronger balance sheet provides a clearer runway to advance clinical programs over the next 2–6 months and lowers the probability of immediate dilutive financing needs.
Cash Flow Aligns With Reported LossesFree cash flow tracking net losses implies reported operating losses are largely cash-based rather than masking non-cash accounting items. This transparency improves forecasting of actual cash runway and capital needs, enabling more reliable near-term planning for R&D spend and financing decisions.
Bears Say
Heavy And Rising Cash BurnPersistent and increasing operating cash outflows (OCF -$66.3M in 2025) create ongoing funding pressure for a company with no product revenue. Over a multi-month horizon, rising burn magnifies the need for external financing and heightens execution risk if clinical timelines slip or additional capital cannot be secured on favorable terms.
Pre-revenue With Widening LossesThe absence of revenue combined with widening operating losses (EBIT -$88.98M; net -$75.27M in 2025) means value creation depends entirely on pipeline progress. This structural reality increases binary outcome risk over the medium term and extends the timeline before the business can generate self-sustaining cash flows.
Negative Returns Despite Stronger EquityEven with a stronger capital base, the company generated a negative ROE (~-24.5% in 2025), indicating that newly raised equity is not yet producing returns. This reflects execution and commercialization risk: capital intensity without near-term revenue increases the risk that future financing will be required before profitability is achieved.
Sionna Therapeutics, Inc. News
SION FAQ
What was Sionna Therapeutics, Inc.’s price range in the past 12 months?
Sionna Therapeutics, Inc. lowest stock price was $13.51 and its highest was $48.45 in the past 12 months.
What is Sionna Therapeutics, Inc.’s market cap?
Sionna Therapeutics, Inc.’s market cap is $1.62B.
When is Sionna Therapeutics, Inc.’s upcoming earnings report date?
Sionna Therapeutics, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 64 days.
How were Sionna Therapeutics, Inc.’s earnings last quarter?
Sionna Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.514 by -$0.086.
Is Sionna Therapeutics, Inc. overvalued?
According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued.
Does Sionna Therapeutics, Inc. pay dividends?
Sionna Therapeutics, Inc. does not currently pay dividends.
What is Sionna Therapeutics, Inc.’s EPS estimate?
Sionna Therapeutics, Inc.’s EPS estimate is -0.65.
How many shares outstanding does Sionna Therapeutics, Inc. have?
Sionna Therapeutics, Inc. has 45,150,330 shares outstanding.
What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?
Sionna Therapeutics, Inc. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.514. Following the earnings report the stock price went down -10.903%.
Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in SION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sionna Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.71 (18.77% Upside)
$51.71 (18.77% Upside)
Blogger Sentiment
Bullish
SION Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 527.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
111.41%
12-Months-Change
Fundamentals
Return on Equity
-27.31%
Trailing 12-Months
Asset Growth
-17.48%
Trailing 12-Months
Company Description
Sionna Therapeutics, Inc.
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
SION Stock 12 Month Forecast
Average Price Target
$51.71
▲(18.77% Upside)
Technical Analysis
Stoke Therapeutics
―
Vir Biotechnology
―
Immatics
―
Tango Therapeutics
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
34.50% Insiders
9.90% Mutual Funds
13.30% Other Institutional Investors
36.38% Public Companies and
Individual Investors